SONOSCAPE released its performance for the first three quarters, with a net profit attributable to the parent company of 33.5111 million yuan, a decrease of 69.25%

SONOSCAPE released its third-quarter report for 2025, with operating revenue of 1.459 billion yuan in the first three quarters, a year-on-year increase of 4.37%. The net profit attributable to the parent company was 33.5111 million yuan, a year-on-year decrease of 69.25%; the net profit after deducting non-recurring gains and losses was 23.991 million yuan, a year-on-year decrease of 72.15%. The basic earnings per share were 0.0774 yuan

SONOSCAPE Supervisory Board approves adjustments and grant proposals related to the incentive plan

The Supervisory Board of SONOSCAPE held a meeting on October 16, 2025, in Shenzhen, where two resolutions were passed: first, to adjust the list of incentive recipients for the 2025 restricted stock and stock option incentive plan, deeming the adjustment to be in compliance with regulations and company policies; second, to grant 1.914 million shares of restricted stock and 3.9678 million stock options to 405 incentive recipients, with the grant date set for [specific month and day] in 2025

SONOSCAPE and Batai Medical officially reached a strategic cooperation

On September 10th, SONOSCAPE officially signed a strategic cooperation agreement with Zhejiang Batai Medical Technology Co., Ltd. in Hangzhou. In response to the growing demand for cardiovascular disease diagnosis and treatment in the current Chinese market, both parties aim to establish a strategic partnership to integrate their respective advantageous resources, focusing on the development and promotion of a new generation of interventional technologies represented by "precise diagnosis and treatment" and "intervention without implantation," to provide more comprehensive and precise treatment options for patients with coronary heart disease in China

The A-share medical device sector fluctuated and rose, with Allgens and United Imaging Healthcare increasing by over 10%. SONOSCAPE, MGI, Double Medical, Tinavi, and Mindray also followed suit

SONOSCAPE plans to grant 1.914 million restricted shares and 3.9678 million stock options

SONOSCAPE plans to grant 1.914 million restricted stocks and 3.9678 million stock options, with the incentive targets including 406 individuals. The grant prices are set at no less than RMB 15.93 per share and RMB 31.86 per option. The validity period of this incentive plan is up to 60 months